Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.59 USD | -2.53% | -1.53% | -10.00% |
May. 01 | RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept | MT |
Apr. 30 | Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Maintained -- Shares Fall After Hours | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.00% | 6.29B | |
+2.93% | 108B | |
-1.02% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B | |
+329.39% | 8.81B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Exelixis : Partner Takeda Secures Cabometyx Combo Nod in Japan for Metastatic Renal Cell Cancer